Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — FY2023 Earnings Presentation
22 slides from Expres2ion Biotech Holding Ab's earnings presentation, Feb 8, 2024
Slide 1: ExpreS2ion Biotechnologies: Presentation of Q4 and full-year 2023 results
Click to edit Master title style ExpreS2ion Biotechnologies - innovative vaccines for a healthier world Presentation of Q4 and full-year 2023 results Hosted by Innovative vaccines for a healthier world
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: Agenda
Agenda • Company profile • Quarterly business update • Financial results Innovative vaccines for a healthier world 3
Slide 4: About ExpreS2ion
About ExpreS2ion ExpreS2ion Biotech Holding AB • Listed on the Nasdaq First North Growth Market since 2016 ExpreS2ion Biotech • Holding company for ExpreS2ion Biotechnologies ApS, Holding AB which it owns 100% ExpreS2ion Biotechnologies ApS 100% • Established in 2010 • Protein expression platform te
Slide 5: Management team
Management team Bent Frandsen Keith Alexander Dr. Farshad Guirakhoo Dr. Max Søgaard CEO CFO CSO SVP of R&D & Technology • MSc in Finance/Strategic Management, • MBA in Finance, The Wharton School of • PhD in Virology, Medical University of 0 • PhD in Biochemistry, University College Copenhagen Busin
Slide 6: ExpreS2 platform
ExpreS2 platform We create the antigen, so the body creates the antibody to fight infection What it does Produce …to create Simplified Vaccine How it adds Competitive Potential antigens… vaccines value advantages enhancements in These • The vaccine • Production speed • Modification of teaches the bo
Slide 7: Delivery vehicles: Why we use virus-like particles (VLPs)
Delivery vehicles Why we use virus-like particles (VLPs) VLP ExpreS2-produced antigens have Replicating Killed been combined with multiple delivery viral whole vehicles and used on their own vectors virus Live attenuated Immunogenicity virus Soluble Replication- mRNA proteins VLPs are virus-derived
Slide 8: ExpreS2 platform proof-of-concept
ExpreS2 platform proof-of-concept Phase III validated Stage Vaccine projects Phase III Bavarian Nordic COVID-19 Phase II 1 x Oxford University Malaria + numerous additional Phase I 3 x Oxford University Malaria pharmaceutical and biotech company protein projects CTA-enabling ES2B-C001 HER2 breast ca
Slide 9: Vaccine pipeline
Vaccine pipeline CTA- Thematic area Program Indication Discovery Lead opt Ph 1 Ph 2 Ph 3 enabling HER2+ Oncology ES2B-C001 breast cancer Tox studies and manufacturing (therapeutic) Cytomegalovirus Infectious disease ES2B-I002 Lead optimization (prevention) Undisclosed Exploratory Undisclosed Discove
Slide 10: Quarterly business update
Quarterly business update Innovative vaccines for a healthier world 10
Slide 11: ES2B-C001 HER2+ breast cancer vaccine
ES2B-C001 HER2+ breast cancer vaccine Q4 progress • Study is complete Preclinical safety • Draft report is near completion • GMP drug substance production initiated in CMC December • Design of Investigator-Initiated Trial (IIT) underway Clinical • Commencement subject to securing adequate funds Busi
Slide 12: ES2B-C001 HER2+ breast cancer vaccine: remaining steps to clinical readiness
ES2B-C001 HER2+ breast cancer vaccine Remaining steps to clinical readiness Nonclinical Regulatory • Preclinical safety study • CTA submission draft and final report • Regulatory green light CMC Clinical • Completion of GMP drug • Protocol revision substance production • Preparation of • Initiation
Slide 13: ES2B-I002 cytomegalovirus vaccine
ES2B-I002 cytomegalovirus vaccine Progress on track • In vivo experiments conducted • Testing immunogenicity • Comparisons with other vaccines • CMC experiments underway • Variants being tested for immunogenicity Project summary • Launched December 2022 with 50/50 cost sharing with Evaxion Biotech •
Slide 14: VICI-Disease project
VICI-Disease project €8 million EU Horizon 2023 grant won, of which 53% goes to ExpreS2ion UCPH 9% Associated partners AV 13% ES2B 53% RUMC 13% FLI 12% Innovative vaccines for a healthier world 14
Slide 15: Financial results
Financial results Innovative vaccines for a healthier world 15
Slide 16: Operating income
Operating income Operating income, SEK ‘000s Net sales, SEK ‘000s Other operating income, SEK ‘000s 5,000 5,000 5,000 Net sales Other operating income 4,000 4,000 4,000 3,000 3,000 3,000 2,000 = 2,000 + 2,000 1,000 1,000 1,000 0 0 0 1Q21 3Q21 1Q22 3Q22 1Q23 3Q23 1Q21 3Q21 1Q22 3Q22 1Q23 3Q23 1Q21 3Q
Slide 17: Operating costs
Operating costs Operating costs, SEK ‘000s 0 -10,000 -20,000 -30,000 -40,000 -50,000 -60,000 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 Innovative vaccines for a healthier world 17
Slide 18: Operating costs composition
Operating costs composition SEK ‘000s R&D costs (external) Personnel costs excl. vesting of share-based compensation 0 0 -12,500 -3,750 -25,000 -7,500 -37,500 -11,250 Volatile & dependent Decreasing; impacted by cost -50,000 upon pipeline activities -15,000 reductions; sensitive to FX and inflation
Slide 19: Profit / loss for the period
Profit / loss for the period 4Q profit / loss, SEK ‘000s Full-year profit / loss, SEK ‘000s 2022 2023 2022 2023 0 0 -12,000 -30,000 -17,817 -24,000 -60,000 -36,000 -90,000 -63% -95,989 -48,000 -120,000 -48,533 -118,605 -19% -60,000 -150,000 Innovative vaccines for a healthier world 19
Slide 20: Cash development in 2023
Cash development in 2023 SEK millions 180 48 150 120 111 90 2 58 60 -103 30 0 December 2022 New Capital Operations and Currency changes December 2023 Investment Activities Innovative vaccines for a healthier world 20
Slide 21: Cash balance
Cash balance SEK millions 200 168 150 150 142 139 125 108 111 100 88 83 77 72 58 50 0 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 Innovative vaccines for a healthier world 21
Slide 22: Contact: Investor Relations
Contact: Investor Relations investor@expreS2ionbio.com Innovative vaccines for a healthier world 22
ExpreS2ion Biotech Holding — FY2023 Earnings Presentation on 6ix